Trials / Completed
CompletedNCT00045981
The SAPPHIRE Study (Systolic And Pulse Pressure Hemodynamic Improvement By Restoring Elasticity)
Systolic and Pulse Pressure Hemodynamic Improvement By Restoring Elasticity: The SAPPHIRE Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 450 (planned)
- Sponsor
- Synvista Therapeutics, Inc · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of ALT-711 in the treatment of isolated systolic hypertension in a formal dose-ranging study in patients without left ventricular hypertrophy. Eligible patients will be randomized to double-blind treatment once daily for 6 months with oral ALT-711 (35, 70, 140, or 210 mg) or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALT-711 |
Timeline
- Start date
- 2001-10-01
- Primary completion
- 2003-05-01
- Completion
- 2006-08-01
- First posted
- 2002-09-19
- Last updated
- 2010-03-26
Source: ClinicalTrials.gov record NCT00045981. Inclusion in this directory is not an endorsement.